Last reviewed · How we verify
Tadalafil- Tablet or Oral suspension
At a glance
| Generic name | Tadalafil- Tablet or Oral suspension |
|---|---|
| Also known as | LY450190 |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject (PHASE1)
- A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH) (PHASE3)
- A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tadalafil- Tablet or Oral suspension CI brief — competitive landscape report
- Tadalafil- Tablet or Oral suspension updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI